These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24440278)

  • 1. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
    Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
    Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
    Lagana SM; Taub RN; Borczuk AC
    Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
    Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
    Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-catenin expression in benign and malignant pleural disorders.
    Anani W; Bruggeman R; Zander DS
    Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
    Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
    Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
    Derakhshan F; Ionescu D; Cheung S; Churg A
    Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma].
    Wei P; Jin ML; Zhao HY; Li X; Diao XL
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):451-4. PubMed ID: 24246863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathohistological diagnosis and differential diagnosis.
    Tischoff I; Neid M; Neumann V; Tannapfel A
    Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
    Hasteh F; Lin GY; Weidner N; Michael CW
    Cancer Cytopathol; 2010 Apr; 118(2):90-6. PubMed ID: 20209622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
    Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
    J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UHRF1 Immunohistochemical Staining Separates Benign Reactive Spindle Cell Mesothelial Proliferations From Sarcomatoid Mesotheliomas.
    Yang H; Cheung S; Churg A
    Am J Surg Pathol; 2022 Jun; 46(6):840-845. PubMed ID: 34772842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
    Tigrani DY; Weydert JA
    Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations.
    Cakir C; Gulluoglu MG; Yilmazbayhan D
    Pathology; 2006 Feb; 38(1):10-5. PubMed ID: 16484001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry of cytokeratins 7, 8, 17, 18, and 19, and GLUT-1 aids differentiation of desmoplastic malignant mesothelioma from fibrous pleuritis.
    Horiuchi T; Ogata S; Tominaga S; Hiroi S; Kawahara K; Hebisawa A; Irei I; Ito I; Kameya T; Tsujimura T; Nakano T; Nakanishi K; Kawai T
    Histol Histopathol; 2013 May; 28(5):663-70. PubMed ID: 23224745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
    Monaco SE; Shuai Y; Bansal M; Krasinskas AM; Dacic S
    Am J Clin Pathol; 2011 Apr; 135(4):619-27. PubMed ID: 21411785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.